PHUSISINC.US
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancermolecule therapeutics, PH-domains, cancer therapy, PLEKHA7 Inhibitors, RAL Inhibitors, Tiam1, CERK inhibitors
http://www.phusisinc.us/
molecule therapeutics, PH-domains, cancer therapy, PLEKHA7 Inhibitors, RAL Inhibitors, Tiam1, CERK inhibitors
http://www.phusisinc.us/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Wednesday
LOAD TIME
0.3 seconds
16x16
PHusis Therapeutics
PHusis Therapeutics
7000 Fan●●●●●●●●ite 2115
Ho●●on , TX, 77030
United States US
View this contact
PHusis Therapeutics
PHusis Therapeutics
7000 Fan●●●●●●●●ite 2115
Ho●●on , TX, 77030
United States US
View this contact
PHusis Therapeutics
Lynn Kirkpatrick
3210 M●●●●●●ed Row
San●●●ego , 92121
CA
View this contact
PHusis Therapeutics
PHusis Therapeutics
7000 Fan●●●●●●●●ite 2115
Ho●●on , TX, 77030
United States US
View this contact
BUY YOUR DOMAIN
Network Solutions Inc.
WHOIS : whois.nic.us
REFERRED :
PAGES IN
THIS WEBSITE
2
SSL
EXTERNAL LINKS
0
SITE IP
206.188.193.30
LOAD TIME
0.313 sec
SCORE
6.2
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer | phusisinc.us Reviews
https://phusisinc.us
molecule therapeutics, PH-domains, cancer therapy, PLEKHA7 Inhibitors, RAL Inhibitors, Tiam1, CERK inhibitors
phusisinc.us
PHusis Therapeutics | About PHusis
http://www.phusisinc.us/Phusis_Therapeutics-About_PHusis.html
PDK1 Inhibitor: PHT - 427. PHusis has built a pipeline of drug leads against some unique cancer targets including PDK1 for mutant NRAS melanoma, and CNKSR1 and PLEK for mutant KRAS in lung and colon cancer, Further refinement and optimizations of these leads will provide agents that will be rapidly advanced through IND enabling studies to clinical trials. PHusis’ first drug candidate, the PDK1 inhibitor PHT-427 has entered IND-enabling preclinical development. Website design by Tribe Design.
PHusis Therapeutics | Management Team
http://www.phusisinc.us/Phusis_Therapeutics-Management-Team.html
PDK1 Inhibitor: PHT - 427. D Lynn Kirkpatrick, PHD. Ms Berenjian has over twenty years of experience as controller and financial analyst in small companies in Southern California. She has been involved with companies in all stages of development, and has managed all aspects of accounting for a compliance banking company. She has co-ordinated diligence activities for companies undergoing acquisition, supervising audits and overseeing the transition of accounting policies into new company. Former CEO Merch...
TOTAL PAGES IN THIS WEBSITE
2
En construction
Site hébergé par OVH.COM. Installer un module clef en main. Mettre votre site en ligne. Gestion des bases MySQL. Taches automatisées (CRON). Discutez avec nos autres utilisateurs sur notre forum. Toujours pas de solution? Ou téléphonez-nous. Les outils à votre disposition :. Votre manager (espace client). De votre hébergement. Installés sur votre hébergement. Suivez l'état de vos services :. Votre serveur d'hébergement : cluster014. Etat de votre hébergement. Netcraft : uptime graph. XA0;- toolbar.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
phusisinc.info
If you are the owner of this domain name, click here to verify. Review our Privacy Policy.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
Phusis/Letter/Lecture...
MARK E.TEMME IS A LEADING THEORIST ON ASTROPHYSICS. Saturday, August 2, 2008. Infinity/God/Universe/Humanity. "A Lecture" By Mark E. Temme (E PLURIBUS UNUM). Unified Field Theory Paper. Successfully" described a unified field starting with the "first cause", which is. Infinity and time being the two driving spacetime "force dimensions". Phusis/Unified Field Theory and "Infinity Equation". In actuality are a continuum with. The "mind of God" or essence. Abbr version) (O.=E=mc2) by: Mark E. Temme. Thus inf...
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
PHusis Therapeutics Delivers Novel PH-Domain Inhibitors for the Treatment of Cancer
PDK1 Inhibitor: PHT - 427. PHusis Delivers Precision Medicines for the Treatment of Cancer. PHusis Therapeutics is developing novel targeted small molecule therapeutics that bind and block the pleckstrin homology (PH)-domain of critical signaling proteins involved in driving cancer cell growth and survival in patients with limited treatment options. 2014 PHusis Therapeutics Inc. 3210 Merryfield Row San Diego, CA 92121 Email us. Website design by Tribe Design.
